Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variation in eye care professional distribution across Europe, a survey.
Arnould L, Varsanyi B, Dervan E, Posarelli C, Filipe HP, Bourcier T, Wedrich A, Ivekovic R, Petrovski G, Porro GL, Laganovska G, Balciuniene VJ, Mrukwa-Kominek E, Paust K, Roemer S, Haefliger IO, Atilla H, Ursell P, Cvenkel B, Kiilgaard J, Grupcheva C, Furdova A, Claeys M, Maresova K, Mercieca F, Sepp T, Parikakis E, Burcea M, Aclimandos W, Khawaja AP. Arnould L, et al. Among authors: laganovska g. Eye (Lond). 2024 Mar 12. doi: 10.1038/s41433-024-03010-7. Online ahead of print. Eye (Lond). 2024. PMID: 38472379 No abstract available.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, Fichtl M, Belda JI, Hommer A, Laganovska G, Schweitzer C, Voykov B, Zarnowski T, Holló G. Stalmans I, et al. Among authors: laganovska g. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):179-190. doi: 10.1007/s00417-023-06192-0. Epub 2023 Aug 24. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37615697 Free PMC article. Clinical Trial.
Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holló G; VISIONARY Study Group. Oddone F, et al. Adv Ther. 2022 Aug;39(8):3522-3523. doi: 10.1007/s12325-022-02210-5. Adv Ther. 2022. PMID: 35731341 Free PMC article. No abstract available.
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holló G; VISIONARY Study Group. Oddone F, et al. Adv Ther. 2022 Aug;39(8):3501-3521. doi: 10.1007/s12325-022-02166-6. Epub 2022 May 7. Adv Ther. 2022. PMID: 35524840 Free PMC article.
34 results